The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Zepbound can now be covered by Medicare
El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...
Ask a Health Professional: How do semaglutide and tirzepatide support wellness goals?
Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
Pharmaceutical Technology9d
Tirzepatide outpacing Wegovy in the obesity space
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...
Yahoo Finance9d
Tirzepatide outpacing Wegovy in the obesity space
According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...